Biologic targeting in the treatment of inflammatory bowel diseases
Matteo Bosani, Sandro Ardizzone, Gabriele Bianchi PorroChair of Gastroenterology, “L. Sacco” University Hospital, Milan, ItalyAbstract: The etiology of inflammatory bowel disease (IBD) has not yet been clarified and immunosuppressive agents which nonspecifically reduce in...
Guardado en:
Autores principales: | Matteo Bosani, Sandro Ardizzone, Gabriele Bianchi Porro |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d1dca0382bc1443b92e11b56a2f07343 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Biologic targeting in the treatment of inflammatory bowel diseases [Retraction]
por: Bosani M, et al.
Publicado: (2014) -
Adalimumab for the treatment of Crohn’s disease
por: Andrea Cassinotti, et al.
Publicado: (2008) -
Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
por: Marafini I, et al.
Publicado: (2020) -
Editorial: Game Changers in Inflammatory Bowel Diseases
por: Anita Bálint, et al.
Publicado: (2021) -
Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais E, et al.
Publicado: (2020)